SG Americas Securities LLC Trims Stock Position in Vera Therapeutics, Inc. $VERA

SG Americas Securities LLC trimmed its holdings in Vera Therapeutics, Inc. (NASDAQ:VERA) by 52.1% during the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 12,651 shares of the company’s stock after selling 13,743 shares during the period. SG Americas Securities LLC’s holdings in Vera Therapeutics were worth $509,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in the business. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its holdings in shares of Vera Therapeutics by 7.7% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 30,905 shares of the company’s stock worth $753,000 after acquiring an additional 2,210 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its position in shares of Vera Therapeutics by 22.4% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 98,013 shares of the company’s stock worth $2,354,000 after acquiring an additional 17,907 shares during the last quarter. Jane Street Group LLC grew its holdings in Vera Therapeutics by 297.1% in the first quarter. Jane Street Group LLC now owns 41,578 shares of the company’s stock valued at $999,000 after purchasing an additional 62,678 shares during the period. JPMorgan Chase & Co. grew its holdings in Vera Therapeutics by 550.5% in the second quarter. JPMorgan Chase & Co. now owns 310,547 shares of the company’s stock valued at $7,316,000 after purchasing an additional 262,805 shares during the period. Finally, Legal & General Group Plc increased its position in Vera Therapeutics by 1.7% during the second quarter. Legal & General Group Plc now owns 50,418 shares of the company’s stock worth $1,188,000 after purchasing an additional 825 shares during the last quarter. Hedge funds and other institutional investors own 99.21% of the company’s stock.

Key Stories Impacting Vera Therapeutics

Here are the key news stories impacting Vera Therapeutics this week:

• Positive Sentiment: The FDA approved TRUTAKNA for primary IgA nephropathy, making it the first and only available therapy targeting both BAFF and APRIL for this kidney disease. Vera Therapeutics Receives FDA Accelerated Approval for TRUTAKNA for Adult Patients with Primary IgA Nephropathy
• Positive Sentiment: Multiple reports said the approval triggered a sharp move in the stock, with investors viewing the drug approval as a key commercial catalyst for Vera Therapeutics. US FDA approves Vera’s kidney disease drug
• Positive Sentiment: Analysts responded favorably after the approval, including HC Wainwright raising its price target to $125 and Bank of America lifting its target to $70, reinforcing expectations for meaningful upside if TRUTAKNA gains traction.
• Neutral Sentiment: Wedbush also increased its price target to $43 and kept a neutral rating, suggesting the approval improved sentiment but left some analysts more cautious on valuation.

Analyst Upgrades and Downgrades

A number of equities analysts have weighed in on VERA shares. William Blair reaffirmed an “outperform” rating on shares of Vera Therapeutics in a research note on Tuesday, June 2nd. HC Wainwright boosted their price objective on shares of Vera Therapeutics from $110.00 to $125.00 and gave the company a “buy” rating in a research note on Wednesday. Bank of America upped their price objective on Vera Therapeutics from $65.00 to $70.00 and gave the stock a “buy” rating in a report on Tuesday. Needham & Company LLC set a $125.00 target price on Vera Therapeutics in a research report on Wednesday. Finally, Jefferies Financial Group reaffirmed a “buy” rating and issued a $60.00 target price on shares of Vera Therapeutics in a research report on Tuesday, June 2nd. Eleven equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $84.58.

Insider Activity at Vera Therapeutics

In other news, CEO Marshall Fordyce sold 22,951 shares of the firm’s stock in a transaction on Tuesday, April 14th. The shares were sold at an average price of $44.05, for a total value of $1,010,991.55. Following the transaction, the chief executive officer owned 235,244 shares of the company’s stock, valued at approximately $10,362,498.20. This trade represents a 8.89% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders have sold 59,951 shares of company stock valued at $2,392,387. Company insiders own 15.90% of the company’s stock.

Vera Therapeutics Stock Down 1.2%

VERA opened at $42.43 on Thursday. The firm has a 50 day moving average price of $36.40 and a 200 day moving average price of $41.16. The company has a market cap of $3.05 billion, a PE ratio of -7.66 and a beta of 0.92. Vera Therapeutics, Inc. has a 1 year low of $19.07 and a 1 year high of $56.05. The company has a debt-to-equity ratio of 0.15, a quick ratio of 13.64 and a current ratio of 13.64.

Vera Therapeutics (NASDAQ:VERA) last announced its quarterly earnings results on Thursday, May 7th. The company reported ($1.69) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.33) by ($0.36). During the same quarter in the previous year, the business earned ($0.81) EPS. Sell-side analysts expect that Vera Therapeutics, Inc. will post -6.23 earnings per share for the current year.

Vera Therapeutics Profile

Vera Therapeutics is a clinical-stage biotechnology company focused on developing novel immunotherapies that harness the body’s own regulatory T cells to treat autoimmune and inflammatory diseases. By leveraging a proprietary protein engineering platform, the company designs Treg-selective cytokine variants intended to restore immune balance and provide targeted, disease-modifying effects. Its pipeline comprises multiple preclinical and clinical candidates aimed at indications characterized by chronic inflammation and autoimmunity.

Founded in 2018 and headquartered in Cambridge, Massachusetts, Vera Therapeutics collaborates with leading academic and research institutions to advance its development programs.